Novartis: Leukemia trials
The registry lists 35 Leukemia studies with Novartis as lead sponsor. 2 are open to participants now and 23 have results posted.
Phase 1 6Phase 2 17Phase 3 9Phase 4 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
- Managed Access Programs for CTL019, TisagenlecleucelAvailableNCT03601442
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
- Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04225676Phase 2Results posted
- Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
- A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
- LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
- Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.TerminatedNCT02108951Phase 3Results posted
- A Safety and Efficacy Study of Eltrombopag in Subjects With AMLCompletedNCT01890746Phase 2Results posted
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.CompletedNCT01844765Phase 2Results posted
- Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute LeukemiaCompletedNCT01826214Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic LeukemiaCompletedNCT01313689Phase 3Results posted
- CMR Rate of Newly Diagnosed CML-CP Patients Treated With NilotinibCompletedNCT01227577Phase 4Results posted
- Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01061177Phase 4Results posted
- An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib TreatmentCompletedNCT00980018Phase 4Results posted
- Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)CompletedNCT00880269Phase 2Results posted
- Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3Results posted
- Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT00782067Phase 2Results posted
- Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)CompletedNCT00760877Phase 3Results posted
- Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
- A Study of Oral LBH589 in Adult Patients With Advanced Hematological MalignanciesCompletedNCT00621244Phase 1/2Results posted
- Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)TerminatedNCT00519090Phase 3Results posted
- A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
- Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseTerminatedNCT00449761Phase 2Results posted
- An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)No longer availableNCT03114228
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
- Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
- Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid LeukemiaTerminatedNCT00279773Phase 1
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
- STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT00006343Phase 3
- STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
- STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2